SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:49PM EDT. Market open.
| Previous close | 43.35 |
| Open | 44.93 |
| Bid | 44.64 x 200 |
| Ask | 44.89 x 100 |
| Day's range | 42.12 - 45.10 |
| 52-week range | 18.00 - 53.92 |
| Volume | |
| Avg. volume | 1,199,680 |
| Market cap | 3.314B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.15 |
| Earnings date | 31 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.78 |
Simply Wall St.Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
GlobeNewswireSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc
© 2024 Yahoo. All rights reserved.